Drug and Device Law (Free subscription) | yesterday
No, we're not talking about the McClellan Kerr Project that turned Little Rock and Tulsa, of all places, into seaports. We're talking consumer protection lawsuits against pharmaceutical companies (aren't we always). We've mentioned a couple of times before that a lot of consumer protection laws contain "safe harbor" provisions that bar suits over conduct that was "authorized"/"approved"/"permitted"...
43(B)log (Free subscription) | 11/07/2009
DePriest v. AstraZeneca Pharmaceuticals, L.P., --- S.W.3d ----, 2009 Ark. 547, 2009 WL 3681868 (Ark.) Plaintiffs sued AstraZeneca for false advertising of Nexium. Prilosec, Nexium’s predecessor, aka “The Purple Pill,” was AZ’s most profitable drug when its patent expired in 2001. In 2001, the FDA approved AZ’s request to market Nexium to treat conditions relating to gastro-esophageal...
Philadelphia Inquirer (Free subscription) | 10/30/2009
Drugmaker AstraZeneca P.L.C. said yesterday that it had set aside $520 million as part of a tentative agreement to resolve an investigation by federal prosecutors in Philadelphia into the company's marketing practices.
Examiner (Free subscription) | 10/29/2009
Pharmaceutical company AstraZeneca PLC posted a 22 percent rise in third quarter net profit on Thursday, boosted by initial sales of its swine flu vaccine and delayed entry of generic drug competition in the United States.
kansascity.com (Free subscription) | 10/29/2009
Pharmaceutical company AstraZeneca PLC has reported an 22 percent rise in third quarter net profit, boosted by initial sales of its swine flu vaccine and delayed entry of generic drug competition in the United States.
Miami Herald (Free subscription) | 10/29/2009
Pharmaceutical company AstraZeneca PLC has reported an 22 percent rise in third quarter net profit, boosted by initial sales of its swine flu vaccine and delayed entry of generic drug competition in the United States.
Seattle Times (Free subscription) | 10/29/2009
Pharmaceutical company AstraZeneca PLC has reported an 22 percent rise in third quarter net profit, boosted by initial sales of its swine flu vaccine and delayed entry of generic drug competition in the United States.
San Diego Union (Free subscription) | 10/29/2009
Pharmaceutical company AstraZeneca PLC has reported an 22 percent rise in third quarter net profit, boosted by initial sales of its swine flu vaccine and delayed entry of generic drug competition in the United States.
Forex Analytics (Free subscription) | 10/29/2009
Healthcare business AstraZeneca PLC (AZN, AZN.L) Wednesday said IT has withdrawn regulatory offres the for using Zactima, or vandetanib, 100mg combination with chemotherapy patients suffering from advanced non-small cell lung, or NSCLC cancer, from les États-Unis FDA the and European Medicines Agency the, or EMEA. More: continued here (c)Autor: Forex Analytics Blog: earn money with [...] Post...
PharmaGossip (Free subscription) | 10/24/2009
A Texas woman is claiming the medication she took for a mental disorder caused her to develop diabetes, and says the medication's risks were not worth the benefits. Misty Peters was taking the drug Seroquel, which is an atypical anti-psychotic that is used for the treatment of schizophrenia, bipolar disorder and other "off-label" uses. Peters filed a product liability lawsuit against AstraZeneca...
Market Wire (Free subscription) | 10/23/2009
NEW DELHI, INDIA (MARKET WIRE) Wallstsense.com is an online community with a dedicated team of analysts who are providing free in-depth research on North American equities. Our analysts have issued complimentary analysis on the following six companies: United States Oil (NYSE Arca: USO), Chico's FAS Inc. (NYSE: CHS), AstraZeneca plc (NYSE: AZN), Hexcel Corp. (NYSE: HXL), Onyx Pharmaceuticals Inc. (NASDAQ:...
Policy and Medicine (Free subscription) | 10/21/2009
Four pharmaceutical companies announced they will pay a total of $124 million nationally as part of a major Medicaid fraud case. North Carolina Attorney General Roy Cooper announced that Mylan Pharmaceuticals, Inc., UDL Laboratories, Inc., AstraZeneca Pharmaceuticals LP, and Ortho...
Net News Publisher (Free subscription) | 10/21/2009
Mylan Pharmaceuticals, UDL Laboratories, AstraZeneca Pharmaceuticals and Ortho McNeil Pharmaceutical have entered into settlement agreements for a total of $124 million to resolve claims that they violated the False Claims Act by failing to pay appropriate rebates to state Medicaid programs for drugs paid for by those programs. The Medicaid Prescription Drug Rebate Program was enacted [...]
PharmaGossip (Free subscription) | 10/20/2009
October 20, 2009 Four pharmaceutical firms have agreed to settlements with a number of states and the federal government and will pay $124 million to resolve claims that they violated the False Claims Act by failing to pay appropriate rebates for drugs that were paid for by Medicaid. Mylan Pharmaceuticals, Inc. (MPI), UDL Laboratories, Inc. (UDL), AstraZeneca Pharmaceuticals LP, and Ortho McNeil Pharmaceutical,...
PharmaGossip (Free subscription) | 10/20/2009
Drugmaker AstraZeneca cutting its US sales force (AP) – 9 hours ago WILMINGTON, Del. — British drugmaker AstraZeneca PLC plans to cut its U.S. sales force by offering buyouts. The maker of cholesterol pill Crestor and anti-psychotic drug Seroquel is asking interested sales representatives to identify themselves. AstraZeneca last week notified its approximately 5,500 U.S. sales representatives....
The last article published by a user on AstraZeneca plc :
aarkstore | 09/11/2009
AstraZeneca PLC - Financial and Strategic Analysis Review Summary : AstraZeneca PLC (AstraZeneca) is a leading pharmaceuticals company engaged in the design, development, production and marketing of a broad range of prescription pharmaceuticals, biologics and vaccines to fight disease in the areas of healthcare; such as cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory...
Videos